Citadel Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-706,864
| Closed | -$17.6M | – | 14031 |
|
|
2020
Q4 | $12M | Buy |
706,864
+665,524
| +1,610% | +$8.34M | ﹤0.01% | 2405 |
|
|
2020
Q3 | $195K | Sell |
41,340
-91,213
| -69% | -$463K | ﹤0.01% | 8827 |
|
|
2020
Q2 | $809K | Buy |
132,553
+3,617
| +3% | +$14.9K | ﹤0.01% | 6220 |
|
|
2020
Q1 | $292K | Sell |
128,936
-23,078
| -15% | -$97.9K | ﹤0.01% | 7391 |
|
|
2019
Q4 | $698K | Sell |
152,014
-67,756
| -31% | -$268K | ﹤0.01% | 6249 |
|
|
2019
Q3 | $851K | Buy |
219,770
+62,295
| +40% | +$342K | ﹤0.01% | 5869 |
|
|
2019
Q2 | $950K | Buy |
157,475
+130,783
| +490% | +$1.25M | ﹤0.01% | 5775 |
|
|
2019
Q1 | $358K | Sell |
26,692
-138,904
| -84% | -$1.58M | ﹤0.01% | 7349 |
|
|
2018
Q4 | $1.54M | Sell |
165,596
-79,739
| -33% | -$949K | ﹤0.01% | 4587 |
|
|
2018
Q3 | $3.42M | Buy |
245,335
+98,288
| +67% | +$1.46M | ﹤0.01% | 3533 |
|
|
2018
Q2 | $2.33M | Buy |
147,047
+71,683
| +95% | +$1.25M | ﹤0.01% | 3876 |
|
|
2018
Q1 | $1.29M | Sell |
75,364
-7,920
| -10% | -$154K | ﹤0.01% | 4415 |
|
|
2017
Q4 | $1.83M | Buy |
+83,284
| New | +$2.68M | ﹤0.01% | 3766 |
|
|
2017
Q2 | – | Sell |
-153,932
| Closed | -$4.8M | – | 8305 |
|
|
2017
Q1 | $5.57M | Buy |
+153,932
| New | +$6.79M | 0.01% | 1942 |
|
|
2016
Q2 | – | Sell |
-9,065
| Closed | -$394K | – | 7635 |
|
|
2016
Q1 | $368K | Sell |
9,065
-256,902
| -97% | -$8.83M | ﹤0.01% | 4828 |
|
|
2015
Q4 | $11M | Buy |
265,967
+57,222
| +27% | +$1.92M | 0.01% | 1200 |
|
|
2015
Q3 | $3.21M | Buy |
+208,745
| New | +$4.49M | ﹤0.01% | 2387 |
|
|
2015
Q1 | – | Sell |
-17,471
| Closed | -$472K | – | 8983 |
|
|
2014
Q4 | $472K | Buy |
17,471
+5,451
| +45% | +$93.8K | ﹤0.01% | 4808 |
|
|
2014
Q3 | $141K | Buy |
+12,020
| New | +$152K | ﹤0.01% | 6072 |
|
Citadel Advisors's FPRX Position: Q1 2021 in Review
Citadel Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 706,864 shares — an estimated $17.6M sold.
Citadel Advisors first reported a position in FPRX in Q3 2014 and held it in 19 quarters. The position peaked at $12M in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.
- Citadel Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
- Citadel Advisors sold 706,864 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $17.6M.
- Citadel Advisors first reported a position in Five Prime Therapeutics, Inc. in Q3 2014 and held it in 19 quarters.
- Citadel Advisors's Five Prime Therapeutics, Inc. position peaked at $12M in Q4 2020.
- 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.
Based on Citadel Advisors's 13F filing for Q1 2021, filed 17 May 2021.